Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameRyvu Therapeutics SA
-
Registration countryPoland
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









